Last updated 10 October 2008

Saturday, 13 September 2008

18:00 to 20:00 Registration  

Sunday, 14 September 2008




08:30 Welcome  
    Welcome Arend Heerschap, Ph.D., Radboud University, Nijmegen, The Netherlands
    Patrick J. Cozzone, Ph.D., Centre de Résonance Magnétique Biologique et Médicale, Marseille, France
09:00   Understanding Lipid in the Tumor Cell
Kristine Glunde, Ph.D., Johns Hopkins University, Baltimore, MD, USA
  Proffered Papers
09:45   Assessment of local differences in phosphocholine and phosphoethanolamine content in human brain tumours by 31P MRSI using 1H - 31P polarisation transfer. - not available
Jannie Wijnen, M.Sc., Department of Radiology, Radboud University Medical Centre Nijmegen
10:00   MRS and Genomic Studies on Choline Metabolism in Ovarian Cancer: from Cells to Patients
Egidio Iorio, Department of Cell Biology and Neurosciences, Istituto Superiore di Sanità, Rome
10:15   Cervix Metabolite Changes Associated with Cancer Measured with 1H CSI in vivo
Geoffrey Payne, Cancer Research UK Clinical Magnetic Resonance Research Group, Institute of Cancer Research and Royal Marsden NHS Foundation Trust, Sutton, UK
10:30 Coffee/ Tea Break
  Poster Session
12:30 Lunch  
14:00   The Tumor Microenvironment - not available
Jacques Pouyssegur, Ph.D., Institute of Signalling, Dev. Biology and Cancer Research, Nice France
  Proffered Papers
14:45   The First Sodium and Diffusion MRI during Chemotherapy of Rodent Glioma at 21T
Victor Schepkin, Ph.D., National High Magnetic Field Lab, FSU, Tallahassee, FL, USA
15:00   Imaging Phospholipase Activity in vivo
James Delikatny, Laboratory of Molecular Imaging, Department of Radiology, University of Pennsylvania, Philadelphia, PA, USA
15:15   CSI-monitored effects of acute hyperglycemia and moderate hypothermia in a glioma mouse model
Rui Simões, Bs.Hon., Bioquímica i Biologia Molecular, Universitat Autònoma de Barcelona, Spain


Coffee/Tea Break

16:00 New MR Insights into Invasion and Metastasis
Paula Foster, Ph.D., Robarts Research Institute, London, UK
Proffered Papers
16:45 Breast and prostate tumor detection using LHRH receptor targeted contrast agent in iMQC and Hyperpolarized 3He experiments
Rosa Branca, Ph.D., Duke University, Durham NC, USA
17:00 Estimating the growth process of gliomas using physiological models
Björn Menze, Ph.D., Harvard Medical School, Boston, MA, USA
17:15 The response of orthotopic prostate tumours to a putative PLCgamma inhibitor in vivo
Jake Burrell, B.Sc., The Institute of Cancer Research, Sutton, Surrey, UK





Controversy: Targeted Contrast Media for Molecular MR Imaging in Cancer – a Valuable Toolset or a Research Cul-de-sac?
Silvio Aime, Ph.D., University of Toronto, Toronto, Canada

    Claire Corot, Ph.D., Guerbet Research, Cedex, France






Monday, 15 September 2008



  William G. Negendank Memorial Lecture
08:30   A Clinical Role for MRS in Cancer Diagnosis and Management
John Griffiths, M.B.B.S., D.Phil., Cancer Research, Cambridge, UK
09:30   13C MR in Cancer – Hyperpolarised and Conventional
Kevin Brindle, D.Phil., University of Cambridge, Cambridge, UK
  Proffered Papers
10:15   Monitoring metabolically active lactate using hyperpolarized 13C MR spectroscopic imaging in a human Glioblastoma Xenograft
Ilwoo Park, Surbeck Laboratory of Advanced Imaging, Department of Radiology and Biomedical Imaging,
University of California, San Francisco, CA, USA
10:30   Combined DCE-MRI and hyperpolarized 13C MRSI indicate anassociation between vascular and metabolic effects of imatinib in a prostate cancer bone metastasis model
Hagit Dafni, Ph.D., Department of Radiology and Biomedical Imaging, University of California, San Francisco, CA, USA
10:45   Hyperpolarized 13C MRS detection of reduced lactate production following PI3K inhibition
Christopher Ward, B.A., Department of Radiology and Biomedical Imaging, University of California, San Francisco, CA, USA
11:00 Coffee/Tea Break
11:30   Newly Emerging Cancer MR Biomarkers – From Discovery to Evaluation in Man
Zaver Bhujwalla, Ph.D., Johns Hopkins University, Baltimore, MD, USA
  Proffered Papers
12:15   Ultra-High Field 1H and 23Na MRI of primary brain tumors: initial experience
Fernando Boada, Ph.D., Department of Radiology, University of Pittsburg Medical Center, Pittsburgh, PA, USA
12:30   Robust estimation of vessel size index from magnitude MRI data
Simon Walker-Samuel, Ph.D., Institute of Cancer Research, Sutton, Surrey, UK
12:45   Properties evaluation of a new MRI contrast agent based on Gd -loaded nano particles coated with nano materials for cell tracking - not available
Riyahi-Alam Nader, Tehran University of Medical Sciences (TUMS), Medical Physics & Biomedical Engineering Department, Tehran, Iran
13:00 Lunch  



Established Cancer MR Biomarkers – from Evaluation to Qualification
  • PME/choline
  • DWI
  • 3D volumetry
Jeffrey L. Evelhoch, Ph.D., Amgen, Inc., Thousand Oaks, CA, USA
  Proffered Papers
14:45   MRI guided anti-tumor therapy with liposomal prednisolone phosphate
Ewelina Kluza, M.Sc., Eindhoven University of Technology, Department of Biomedical Engineering, Biomedical NMR, Eindhoven, The Netherlands
15:00   Magnetic resonance imaging characterization of a murine model of radiation necrosis
Sarah Jost, M.D., Washington University, St. Louis, MO, USA
15:15   1H MRSI detection of elevated total creatine in brain cancer:
a cautionary tale

Dikoma Shungu, Ph.D., Department of Radiology, Weill Cornell Medical College, New York, NY, USA




15:30 Coffee/Tea Break
16:00   Whole Body DWI Screening
Michael Jacobs, Ph.D., Johns Hopkins University, Baltimore, MD, USA





Tuesday, 16 September 2008



08:30   Imaging and Cancer Stem Cells
Rolf Bjerkvig, Ph.D., University of Bergen, Bergen, Norway
09:15 Coffee/Tea Break
09:45   Clinical Trials and Routine Clinical Use:  How to Present the MR Information So Clinicians Can Make Best Use of It
Sarah Nelson, Ph.D., University of California San Francisco, San Francisco, CA, USA
  Proffered Papers
10:30   Multiparametric MR exam (MRI/MRSI/DTI/DCE) using 3T without endorectal coil for clinical detection of prostate cancer: correlation with histopathology
Kirsten Selnæs, Department of Circulation and Medical Imaging, NTNU, Trondheim, Norway
10:45   Integration of Diffusion Weighted Imaging and fMRI to identify differential fiber loss in pre-surgical planning
Fernando Boada, Ph.D., Department of Radiology University of Pittsburgh Medical Center, Pittsburg, PA, USA
11:00   Differentiating tumor vs. pseudotumoural disease vs. normal brain with SV 1H-MRS
Julià-Sapé, Ph.D., Centrode Investigación Biomédica en Red en Bioingeniería, Biomateriales y Nanomedicina (CIBER-BBN), Cerdanyola del Vallès, Barcelona, Spain
11:15   Two radiological advances concerning prostate cancer: what's hot and what's not?
Tom Scheenen, Ph.D., Department of Radiology, Radboud University Nijmegen Medical Centre, Nijmegen, The Netherlands
11:30   Correlation between HRMAS and histopathology in human glioma biopsies
Franklyn Howe, D.Phil., St George’s, University of London, London, UK
11:45   Limitations of the modified-Tofts tracer kinetic model for cancer biomarker studies
David Buckley, Ph.D., Imaging Science & Biomedical Engineering, University of Manchester, Manchester, UK





The International Society for Magnetic Resonance in Medicine is accredited
by the  Accreditation Council for Continuing Medical Education to provide
continuing medical education for physicians.